Targeting menin for precision therapy in high-risk acute myeloid leukemia
Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinica...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Elsevier
2025-01-01
|
| Colección: | Leukemia Research Reports |
| Materias: | |
| Acceso en línea: | http://www.sciencedirect.com/science/article/pii/S2213048924000852 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|